Question
Is there an association between gastric cancer and the use of proton pump inhibitors?
Conclusion
This is the strongest evidence to date that there is a small but clinically significant increase in the risk of gastric cancer for patients taking a PPI (number needed to treat to harm = 1191 over 10 years). Physicians initiating anti-acid therapy for patients should begin with an H2RA, and if prescribing a PPI, should use the lowest dose and duration possible. Another recent study in the same journal using data from a Korean registry produced similar findings (Gut 2021;70:2066-2075 doi:10.1136/gutjnl-2020-323845).
Reference
Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut 2022;71(1):16-24.
Recent Posts
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Is there an association between gastric cancer and the use of proton pump inhibitors?
- Is leukocyte-rich plasma less effective than leukocyte-poor plasma when injected into the knees of adults with osteoarthritis?
- Is an intramuscular glucocorticoid injection noninferior to an intra-articular glucocorticoid injection in reducing knee pain in adults with knee osteoarthritis?
- Are postoperative opioids more effective than nonopioids in reducing pain after minor or moderate surgical procedures?